Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature
Timothy I. Michaels, Jennifer Purdon, Alexis Collins, et al.
BMC Psychiatry (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 184

Showing 1-25 of 184 citing articles:

Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
Alan K. Davis, Frederick S. Barrett, Roland R. Griffiths
Journal of Contextual Behavioral Science (2019) Vol. 15, pp. 39-45
Open Access | Times Cited: 281
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Gabrielle Agin-Liebes, Tara C. Malone, Matthew M. Yalch, et al.
Journal of Psychopharmacology (2020) Vol. 34, Iss. 2, pp. 155-166
Closed Access | Times Cited: 262
Single-Dose Psilocybin Treatment for Major Depressive Disorder
Charles L. Raison, Gerard Sanacora, Joshua D. Woolley, et al.
JAMA (2023) Vol. 330, Iss. 9, pp. 843-843
Open Access | Times Cited: 230
Long-term effects of psychedelic drugs: A systematic review
Jacob S. Aday, Cayla M. Mitzkovitz, Emily K. Bloesch, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 113, pp. 179-189
Closed Access | Times Cited: 184
The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and ethnic minority inclusion
Jamilah R. George, Timothy I. Michaels, Jae Sevelius, et al.
Journal of Psychedelic Studies (2019) Vol. 4, Iss. 1, pp. 4-15
Open Access | Times Cited: 157
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 10, pp. 1100-1117
Open Access | Times Cited: 127
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Jordan Sloshower, Patrick D. Skosnik, Hamideh Safi-Aghdam, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 698-706
Closed Access | Times Cited: 85
History repeating: guidelines to address common problems in psychedelic science
Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 51
Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies
Natacha Perez, Florent Langlest, Luc Mallet, et al.
European Neuropsychopharmacology (2023) Vol. 76, pp. 61-76
Open Access | Times Cited: 41
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 40
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Athina-Marina Metaxa, Mike Clarke
BMJ (2024), pp. e078084-e078084
Open Access | Times Cited: 21
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
Stephanie L. Haft, Amanda E. Downey, Marissa Raymond‐Flesch, et al.
Psychiatry Research (2025) Vol. 345, pp. 116359-116359
Open Access | Times Cited: 3
Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame
Jordan Sloshower, Jeffrey Guss, Robert Krause, et al.
Journal of Contextual Behavioral Science (2019) Vol. 15, pp. 12-19
Closed Access | Times Cited: 126
Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy
Natalie Gukasyan, Sandeep M. Nayak
Transcultural Psychiatry (2021) Vol. 59, Iss. 5, pp. 652-664
Closed Access | Times Cited: 102
Ethical and legal issues in psychedelic harm reduction and integration therapy
Brian Pilecki, Jason B. Luoma, Geoff J. Bathje, et al.
Harm Reduction Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 83
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences
Monnica T. Williams, Alan K. Davis, Yitong Xin, et al.
Drugs Education Prevention and Policy (2020) Vol. 28, Iss. 3, pp. 215-226
Open Access | Times Cited: 77
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Kyle T. Greenway, Nicolas Garel, Lisa Jerome, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 6, pp. 655-670
Closed Access | Times Cited: 72
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches
Albert Garcia‐Romeu, Frederick S. Barrett, Theresa M. Carbonaro, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 353-361
Open Access | Times Cited: 72
Working with Weirdness: A Response to “Moving Past Mysticism in Psychedelic Science”
Joost J. Breeksema, Michiel van Elk
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 4, pp. 1471-1474
Open Access | Times Cited: 59
Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment
Johannes Thrul, Albert Garcia‐Romeu
Drugs Education Prevention and Policy (2021) Vol. 28, Iss. 3, pp. 211-214
Open Access | Times Cited: 58
The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics
Aviad Hadar, Jonathan David, Nadav Shalit, et al.
Journal of Psychoactive Drugs (2022) Vol. 55, Iss. 1, pp. 1-10
Closed Access | Times Cited: 56
Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model
Bill Brennan, Alexander B. Belser
Frontiers in Psychology (2022) Vol. 13
Open Access | Times Cited: 50
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
Emma Morton, Kimberly Sakai, Amir Ashtari, et al.
Journal of Psychopharmacology (2022) Vol. 37, Iss. 1, pp. 49-60
Open Access | Times Cited: 45
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision
Darron T. Smith, Sonya C. Faber, NiCole T. Buchanan, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 44
Page 1 - Next Page

Scroll to top